New combo vaccine for infants shows promise in small trial
NCT ID NCT03188692
First seen Jan 08, 2026 · Last updated Jun 20, 2026 · Updated 23 times
Summary
This completed Phase 3 study tested a combined vaccine called BK1310 in 33 healthy infants. The vaccine aims to protect against diphtheria, tetanus, pertussis, polio, and Hib with a series of injections. Researchers measured antibody levels to see if the vaccine triggers a strong immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNIZATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational site 1
Chiba, Japan
-
Investigational site 2
Tokyo, Japan
-
Investigational site 3
Tokyo, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BK1310 (combined DPT-IPV-Hib vaccine)
What this could lead to
If successful, this vaccine could protect infants against diphtheria, tetanus, pertussis, polio, and Hib with a single shot series.
What could go wrong
This is a small, completed Phase 3 trial with only 33 infants, so results may not apply to larger populations. Vaccine side effects like fever or allergic reactions are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.